Definium Therapeutics

It’s been an incredibly exciting few days for those of us invested in advancing psychedelic treatment options, and we’re thrilled to keep up the momentum!     Today we held our Investor & Analyst Day in New York City. Alongside distinguished clinicians, our executive team discussed the evolving treatment landscape in psychiatry, persistent unmet needs, and emerging opportunities to improve outcomes for patients.    We fielded thoughtful questions from the gathered participants and were pleased to share details about our phase 3 clinical program, including three topline readouts anticipated this year, across generalized anxiety disorder (GAD) and major depressive disorder (MDD). We also unveiled that in 2027, we will be expanding our trial program with the Phase 3 HAVEN study in PTSD, broadening the potential impact of our research to veterans, who are among those most acutely affected by the nation’s current mental health crisis.     We are moving with sharpened focus and urgency, while ensuring we maintain the highest standards for clinical trials and regulatory pathways.     For more insights from today’s event, including how we plan to fuel our next phase of growth and deliver meaningful, long-term value for both shareholders and patients, visit: https://bit.ly/4sTL8Uq #InvestorRelations #MentalHealth #Neuroscience #HealthcareInnovation

Definium is pleased to be highlighted as one of several organizations featured in The White House release accompanying the Executive Order advancing breakthrough mental health treatments for patients in need.   This groundbreaking Executive Order accelerates research and improves access to psychedelic therapies for serious mental illness, prioritizing innovations that could bring new hope to millions of Americans, especially veterans who face disproportionately high suicide rates and often do not respond to conventional treatments.   This is a clear call to action—and our work is directly aligned with that mandate.   We are advancing therapies for major depressive disorder (MDD) and generalized anxiety disorder (GAD), which are two of the most prevalent and overlapping conditions in the veteran community: ▪︎ ~50% of veterans with PTSD also have MDD ▪︎ ~40% of veterans with PTSD also have GAD ▪︎ Among veterans, 20% have MDD and 9-15% have PTSD By targeting these high-burden, highly comorbid disorders, all of which are associated with suicide, we are supporting the Executive Order’s objective to expand treatment options and improve outcomes for those who have served. https://bit.ly/3QnjqSr #DefiniumTherapeutics #Biotech #Neuroscience #MentalHealthInnovation #Psychedelics #BrainHealth 

Momentum is building.    This weekend, The White House issued an Executive Order to accelerate research, development and access for psychedelic treatments targeting serious mental illness.    We applaud this critical step, which underscores the vast amount of progress being made to bring novel treatments and hope to the millions of people who live with these disorders around the country.    Alongside our partners in the industry, brought together by the Association for Prescription Psychedelics, we are ready to meet this moment.    We remain committed to advancing rigorous clinical science and the FDA’s evidence-based approval process to provide the most effective path to safely delivering these therapies to patients.     Join us in recognizing the continued progress, and read our statement on the Executive Order here: https://bit.ly/4tX665M    #DefiniumTherapeutics #Biotech  #Neuroscience #MentalHealthInnovation #BrainHealth

At Definium, we are using rigorous science to reshape the conversation around mental health treatment. Hear from David Feifel, MD, PhD, Founder and President at Kadima Neuropsychiatry Institute, on the potential pharmaceutical LSD could offer patients. Keep an eye out for more of Dr. Feifel’s thoughts on this topic. Learn more about how we’re Rerouting Minds here: https://bit.ly/4qqoLVo #Sponsored #MentalHealthInnovation #DefiniumTheraputics #Biotech #Neuroscience #BrainHealth #ReroutingMinds

Our Chief Medical Officer, Dan Karlin, will moderate today at the 2026 CMO Summit 360°.  The session focuses on human and technological solutions to ensure effective and efficient clinical operations. Today, Monday, 4/13 5:00 - 5:30 PM ET Fairmont Copley Plaza Boston, MA More Details: https://lnkd.in/gWZhBkxn #CMOSummit #ClinicalDevelopment #Biotech

So proud to see our CEO, Robert Barrow, share his insights on what it takes to make a big bet and create lasting change in Fast Company. Rob highlights our profound commitment to addressing the mental health crisis by exploring the potential of psychedelic treatment, underscoring the rigorous science, deep education, and critical collaboration required to bring about a meaningful shift in mental health. Check out the full article here: https://bit.ly/4m7nB0z #DefiniumTherapeutics #Biotech #Neuroscience #MentalHealthInnovation #BrainHealth

We will be joining a series of investor conversations this spring—sharing how we’re forging a new era of psychiatry. These events bring together investors, researchers, and industry leaders to explore how new approaches to treatment can address the underlying causes of psychiatric and neurological disorders. Read the full press release for details, access information, and webcast links: https://lnkd.in/gYe_9hfs

At Definium, we are forging a new era of psychiatry by applying scientific rigor to psychedelics—developing accessible treatments that unlock healing at scale. Together we are moving psychiatry forward—beyond better, into a boundless future. Join us. Explore opportunities: https://lnkd.in/gJ22KWXQ #BiotechCareers #Hiring 

Generalized anxiety disorder (GAD) remains one of the most common psychiatric disorders, with little treatment innovation in decades. Our new research in the Journal of Mood & Anxiety Disorders shows a growing burden, now affecting more than 1 in 10 U.S. adults. Add in high comorbidity with major depressive disorder (MDD) and consistently high incidence rates, and the picture is clear: More patients are seeking support than previously reported. It’s time to rethink what’s possible for patients living with GAD. That’s our work ahead. Learn more: https://bit.ly/4s0KJin #MentalHealth #GAD #MDD #HEOR

National Doctors’ Day (NDD) is a nationwide observance honoring physicians for their expertise, responsibility, and continued commitment to patient care.  Progress in brain health depends on discipline, responsibility, and a commitment to science. Every day, physicians apply clinical expertise, careful judgment, and compassion to support patients navigating complex mental health conditions. Today, we thank all physicians, including those who partner with us on our clinical studies to advance mental health care. Learn more: https://lnkd.in/gPfb4xcr #NationalDoctorsDay #ThankYouDoctors #MentalHealth #BrainHealth #DefiniumTherapeutics